Peptide
BPC-157
Body Protection Compound 157
A 15-amino-acid fragment derived from a protein found in gastric juice. Heavy animal-model evidence for tendon and gut repair, zero completed human RCTs.
Summary Does BPC-157 really help heal injuries? Show / hide ↓
BPC-157 is a small chain of 15 amino acids found in a protein from gastric juice. Studies in rats and mice suggest it may speed healing of tendons, muscles, gut injuries, and burns, but these are animal studies. There are no completed human randomized controlled trials, meaning studies that compare the treatment fairly with a placebo or another treatment. Human long-term safety is unknown, and the FDA restricted its use by US compounding pharmacies in November 2023. Some clinics still suggest injections of 250 to 500 micrograms once or twice daily, but this use is not supported by reliable human evidence.
What this means for you: BPC-157 looks promising in animals, but there is not enough human evidence to recommend buying or using it. Its long-term safety is unknown.
weak evidenceBPC-157 has become the most-searched peptide in longevity and biohacking forums, driven almost entirely by animal work and anecdotal reports from athletes rehabbing soft-tissue injuries. The evidence base is genuinely interesting, and genuinely thin.
In rat models the peptide accelerates healing of Achilles tendons, medial collateral ligaments, gut mucosal injury, muscle crush injury, and burn wounds. The mechanism is not fully mapped, but nitric oxide signaling, VEGF release, and modulation of growth-factor receptors appear central. Injected or given orally, the peptide is remarkably well-tolerated at supratherapeutic doses across dozens of rat and mouse studies.
Human evidence is where the story stops. As of 2026, there is no completed, peer-reviewed randomized controlled trial of BPC-157 in humans for any indication. One phase 1 trial of a related synthetic derivative (PL 14736) reached the literature in the mid-2000s for ulcerative colitis. That trial ended without a phase 2. No commercial pharma pipeline currently lists BPC-157 as an active clinical candidate.
In November 2023 the FDA moved BPC-157 off its 503A bulk drug substances list, meaning compliant compounding pharmacies can no longer legally prepare it for human administration in the United States. Prescriptions written after that ruling have been through non-compliant channels. The FDA cited insufficient safety data and unresolved manufacturing questions.
Inside the anti-aging clinical community, some physicians still prescribe or recommend BPC-157 off-label, typically as a subcutaneous injection at 250-500 mcg once or twice daily for 4-8 weeks around a soft-tissue injury. The reported side effect profile is quiet: injection site reactions, occasional GI upset, headache. Long-term human safety data does not exist.
Our position: BPC-157 sits at Tier 5 for humans (mechanistic and animal evidence only, no human RCT), Tier 2 in rodents (large, replicated preclinical body). If you are considering it, verify the source publishes a certificate of analysis showing peptide purity and identity, and understand that you are the human trial.
BPC-157 has strong animal data and near-zero controlled human data, and the FDA's own scientists recommended against compounding access even after an advisory panel voted for it in July 2026.
Verified 2026-08-06. We update this section as PCAC decisions, ClinicalTrials.gov entries, and new peer-reviewed studies land.
FDA / PCAC (July 2026)
Reviewed July 23-24, 2026. The PCAC voted 8-6-1 (yes-no-abstain) to recommend BPC-157 for the 503A Bulks List, against FDA staff's own briefing document, which recommended against inclusion citing angiogenesis and tumor-pathway concerns and no adequate human safety data (https://www.fda.gov/media/193343/download). The vote is advisory and non-binding; no rulemaking has started (https://validusbio.com/learn/pcac-2026-peptide-vote-results/).
US status
Not FDA approved for any indication; removed from FDA's Category 2 bulk substances list on April 15, 2026 after its nomination was withdrawn, which restricts rather than expands compounding access despite the PCAC vote (https://www.jdsupra.com/legalnews/fda-announces-removal-of-12-peptides-3731131/).
EU status
Not authorised for human use in EU as of 2026.
Best-supported claim
A phase 2 randomized, double-blind, placebo-controlled trial for MRI-confirmed grade II hamstring strain is now recruiting (NCT07437547), the first genuine RCT for the compound (https://clinicaltrials.gov/study/NCT07437547). A 2025 systematic review of 36 studies from 1993-2024 found consistent tendon, ligament, muscle, and bone healing signals in animal models, with one retrospective case series reporting 7 of 12 patients pain-free for more than six months after a single knee injection (https://pubmed.ncbi.nlm.nih.gov/40756949/). This is mechanistic and preclinical support, not proof of efficacy in humans.
Not supported by the evidence base
Vendor sites and forums market BPC-157 as a cure for gut permeability, ulcerative colitis, and general joint pain based entirely on rodent gastric-ulcer studies. No RCT has tested it in any human GI disease. Claims that it accelerates tendon or ligament repair in athletes rest on a single small retrospective case series and animal models, not controlled human trials (https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/). The half-life is under 30 minutes in plasma, yet sellers claim effects last days without explaining the pharmacokinetic gap. "Clinically proven" language on retail sites is not supported by any completed human efficacy trial.
Typical usage
250-500 mcg subcutaneous injection, once or twice daily, near the injury site, in 4-6 week cycles in compounding and self-administration protocols; no clinical dosing standard exists because no completed human efficacy trial has established one.
Safety
No long-term human safety data exist beyond a two-person infusion pilot and case reports. FDA's briefing document flags unassessed immunogenicity risk for injectable peptide formulations and unresolved concerns about angiogenesis and tumor-growth pathways given the mechanism of action (https://www.fda.gov/media/193343/download). Injection-site irritation, redness, and swelling are the most commonly reported adverse effects in user reports; sterile technique and verified sourcing matter because compounded and gray-market vials vary in purity. Anyone with active or prior cancer, or who is pregnant, should avoid it given the unassessed angiogenic mechanism.
Interactions worth flagging
- No formal drug-interaction studies exist
- Theoretical concern with anticoagulants given wound-healing/angiogenesis mechanism
- Unknown interaction risk when combined with other unregulated research peptides (stacking)
Three recent studies to know
-
BPC 157 for Acute Hamstring Muscle Strain Repair (BPC-HAMSTR)
First randomized, double-blind, placebo-controlled phase 2 trial of BPC-157 for MRI-confirmed grade II hamstring strain is currently recruiting.
Read study → -
Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study
IV infusion up to 20 mg produced no measurable effects on cardiac, hepatic, renal, thyroid, or glucose biomarkers in two adults.
Read study → -
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review
Review of 36 studies (1993-2024) found consistent preclinical healing signals for muscle, tendon, ligament, and bone injury but almost no controlled human data.
Read study →
Further reading
Curated external sources for a deeper dive. External links open in a new tab.